Possible Side Effects and Safety Considerations Both berberine and L-carnitine are generally considered safe when used appropriately, but each carries potential adverse effects that users should be aware of, particularly when considering concurrent use
When atherosclerotic plaques rupture or endothelial integrity is compromised, rapid platelet aggregation occurs, activating the coagulation cascade and culminating in thrombus formation
Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
1 EC is mainly categorized into two histological subtypes, squamous-cell carcinoma (SCC) and adenocarcinoma (AC), which differ substantially in their geographical distribution, etiology, and pathogenesis
Mid-portion tendinopathy typically responds faster than insertional problems due to easier injection access and slightly better baseline vascularity